Treatment Resistant Bipolar Depression
- Registration Number
- NCT00272025
- Lead Sponsor
- Queen's University
- Brief Summary
To determine if adding Escitalopram to current mood stabilizer (MS) or atypical antipsychotic (AA) will improve in rates similar to or better than adding a placebo (inactive pill)in resistant bipolar patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
- Age 18 or older
- Diagnosis of Bipolar Disorder and currently be in depressive state, and not responded to mood stabilizer or atypical antipsychotic alone or combined with an antidepressant medication.
Exclusion Criteria
- Pregnant or breastfeeding
- History of seizure disorder or other unstable medical condition
- Received Electroconvulsive Therapy or Transcranial Magnetic Stimulation in the last three months
- Experienced hallucinations or delusions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Escitalopram There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine) 2 placebo to be filled in
- Primary Outcome Measures
Name Time Method To evaluate the response rates when Escitalopram vs. placeboes added to the current mood stabilizer or antipsychotic medication 6 weeks
- Secondary Outcome Measures
Name Time Method To evaluate efficacy, safety and tolerability of added Escitalopram, to a mood stabilizer or atypical antipsychotic. 6 weeks
Trial Locations
- Locations (1)
Providence Care, Mental Health Services
🇨🇦Kingston, Ontario, Canada